List of Cellectis patents

Patents where

Current Assignee

Name

Cellectis

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 8979818 Method and apparatus for the delivery of polynucleotide vaccines to mammalian skin	Patent 8979818 was granted and assigned to Cellectis on March, 2015 by the United States Patent and Trademark Office.		Cellectis	United States Patent and Trademark Office	8979818	March 17, 2015
‌ US Patent 10286007 Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells	Patent 10286007 was granted and assigned to Cellectis on May, 2019 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10286007	May 14, 2019
‌ US Patent 11274316 Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells	Patent 11274316 was granted and assigned to Cellectis on March, 2022 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	11274316	March 15, 2022
‌ US Patent 10239948 Method of engineering multi-input signal sensitive T cell for immunotherapy	Patent 10239948 was granted and assigned to Cellectis on March, 2019 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10239948	March 26, 2019
‌ US Patent 11466291 Sequential gene editing in primary immune cells	Patent 11466291 was granted and assigned to Cellectis on October, 2022 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	11466291	October 11, 2022
‌ US Patent 11603539 Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy	Patent 11603539 was granted and assigned to Cellectis on March, 2023 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	11603539	March 14, 2023
‌ US Patent 11304975 Methods for engineering allogeneic and highly active t cell for immunotherapy		Cellectis	Cellectis	United States Patent and Trademark Office	11304975	April 19, 2022
‌ US Patent 10584352 Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system	Patent 10584352 was granted and assigned to Cellectis on March, 2020 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10584352	March 10, 2020
‌ US Patent 9855297 Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system	Patent 9855297 was granted and assigned to Cellectis on January, 2018 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	9855297	January 2, 2018
‌ US Patent 11414674 Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cells		Cellectis	Cellectis	United States Patent and Trademark Office	11414674	August 16, 2022
‌ US Patent 9315788 Method for the generation of compact TALE-nucleases and uses thereof	Patent 9315788 was granted and assigned to Cellectis on April, 2016 by the United States Patent and Trademark Office.		Cellectis	United States Patent and Trademark Office	9315788	April 19, 2016
‌ US Patent 9890393 Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease system	Patent 9890393 was granted and assigned to Cellectis on February, 2018 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	9890393	February 13, 2018
‌ US Patent 7098031 Random integration of a polynucleotide by in vivo linearization	Patent 7098031 was granted and assigned to Cellectis on August, 2006 by the United States Patent and Trademark Office.		Cellectis	United States Patent and Trademark Office	7098031	August 29, 2006
‌ US Patent 11311575 Methods for engineering highly active T cell for immunotherapy		Cellectis	Cellectis	United States Patent and Trademark Office	11311575	April 26, 2022
‌ US Patent 11498971 BCMA (CD269) specific chimeric antigen receptors for cancer immunotherapy	Patent 11498971 was granted and assigned to Cellectis on November, 2022 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	11498971	November 15, 2022
‌ US Patent 11365430 Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system		Cellectis	Cellectis	United States Patent and Trademark Office	11365430	June 21, 2022
‌ US Patent 9944702 CD33 specific chimeric antigen receptors for cancer immunotherapy	Patent 9944702 was granted and assigned to Cellectis on April, 2018 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	9944702	April 17, 2018
‌ US Patent 9944709 CD123 specific chimeric antigen receptors for cancer immunotherapy	Patent 9944709 was granted and assigned to Cellectis on April, 2018 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	9944709	April 17, 2018
‌ US Patent 10988541 CD123 specific chimeric antigen receptors for cancer immunotherapy	Patent 10988541 was granted and assigned to Cellectis on April, 2021 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10988541	April 27, 2021
‌ US Patent 11690873 Universal chimeric antigen receptor T cells specific for CD22	Patent 11690873 was granted and assigned to Cellectis on July, 2023 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	11690873	July 4, 2023
‌ US Patent 10378026 RNA based method to obtain stably integrated retroviral vectors	Patent 10378026 was granted and assigned to Cellectis on August, 2019 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10378026	August 13, 2019
‌ US Patent 11014989 Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy	Patent 11014989 was granted and assigned to Cellectis on May, 2021 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	11014989	May 25, 2021
‌ US Patent 10472613 Method for modulating car-induced immune cells activity	Patent 10472613 was granted and assigned to Cellectis on November, 2019 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10472613	November 12, 2019
‌ US Patent 11578318 Large volume ex vivo electroporation method		Cellectis	Cellectis	United States Patent and Trademark Office	11578318	February 14, 2023
‌ US Patent 10815500 Transcription activator-like effector (TALE) fusion protein	Patent 10815500 was granted and assigned to Cellectis on October, 2020 by the United States Patent and Trademark Office.	Cellectis	Cellectis	United States Patent and Trademark Office	10815500	October 27, 2020

Results per page:

86 results

0 selected

86 results

0 selected